A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients from 6 to Less than 18 Years of Age with Moderate to Severe Plaque Psoriasis - Trial 2019-004141-32
Access comprehensive clinical trial information for 2019-004141-32 through Pure Global AI's free database. This phase not specified trial is sponsored by AbbVie Deutschland GmbH & Co. KG and is currently status unknown. The study focuses on Plaque Psoriasis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AbbVie Deutschland GmbH & Co. KG
AbbVie Inc.
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Concurrent clinically significant medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the participant's participation in this study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk by participating in the study.
ICD-10 Classifications
Data Source
EU Clinical Trials Register
2019-004141-32
Non-Device Trial